Skin & hair

The First Cream Approved to Repigment Vitiligo

Save

Vitiligo has historically been treated with off-label creams and phototherapy, but Opzelura is the first topical medication with an FDA approval specifically for repigmenting it. This article explains how the drug works, what its two pivotal trials actually measured, how results compare with phototherapy alone, and what a realistic timeline for visible repigmentation looks like.

Last updated: July 2026

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

What Ruxolitinib Cream Actually Is

Vitiligo is a chronic autoimmune condition in which the immune system destroys melanocytes, the pigment-producing cells in skin, leaving depigmented, milky-white patches that can appear anywhere on the body and, until recently, had no FDA-approved treatment aimed specifically at bringing pigment back 2. Topical ruxolitinib — brand name Opzelura — is a JAK inhibitor cream, meaning it blocks a specific immune signaling pathway that autoimmune attacks on melanocytes rely on, rather than broadly suppressing the immune system the way some older treatments do.

It's approved for nonsegmental vitiligo — the more common form, where patches tend to appear on both sides of the body somewhat symmetrically — in people aged 12 and older, based on two large phase 3 trials 1.

What the Pivotal Trials Actually Showed

The approval rests on two identically designed phase 3 trials, TRuE-V1 and TRuE-V2, which randomly assigned people with nonsegmental vitiligo to twice-daily ruxolitinib cream or an inactive vehicle cream for 24 weeks, followed by continued open-label treatment 1. About three in ten people using ruxolitinib achieved substantial facial repigmentation by 24 weeks, compared with roughly one in ten on vehicle cream — a clear, statistically significant difference, though it also means most users had not reached that threshold yet at six months.

Results kept improving with continued use: repigmentation rates were meaningfully higher after a full year than at 24 weeks, which is the basis for describing this as a slow, cumulative treatment rather than one with a fast payoff. Body areas away from the face — hands especially — tend to repigment more slowly and less completely than the face, a pattern consistent across both trials 1.

How It Compares With Phototherapy

Narrowband UVB phototherapy has been a mainstay of vitiligo treatment for years longer than ruxolitinib has existed, and a systematic review and meta-analysis found it produces meaningful repigmentation on its own, with response continuing to build over months of consistent treatment 3. The two approaches work through different mechanisms — phototherapy stimulates remaining melanocytes and melanocyte precursors directly with light, while ruxolitinib works by interrupting the immune signal attacking them — which is part of why combining phototherapy and cream for vitiligo is common practice rather than a choice between one or the other.

Neither treatment is fast. Both typically require months of consistent use before repigmentation becomes visually obvious, and both tend to work better on the face than on the hands and feet, likely because those areas have fewer of the hair-follicle pigment reservoirs that repigmentation draws from.

What Using It Actually Looks Like

Ruxolitinib cream is applied to affected areas, and because it works by allowing melanocyte activity to gradually resume rather than through an immediate chemical effect, visible change typically takes months rather than weeks to appear. A patch that looks unchanged after four or six weeks isn't necessarily a sign the treatment has failed — the trials that established its effectiveness measured results at 24 weeks and a full year, not at one month.

Some sun exposure to treated areas is generally encouraged as part of treatment, since UV light is part of what stimulates melanocyte activity, which is also why phototherapy and ruxolitinib are often used together rather than as competing options. Consistent, correct use over many months, rather than a search for a faster alternative, is what the evidence behind this medication actually supports.

Where It Fits Among Other Vitiligo Treatments

Ruxolitinib cream usually enters the conversation after, or alongside, the vitiligo first-line creams already used for new, limited patches — topical corticosteroids and topical calcineurin inhibitors like tacrolimus — rather than replacing them outright for everyone. For vitiligo that's stable but hasn't responded well to those first-line creams, or for people who've developed steroid-related skin thinning from long-term use, ruxolitinib offers a different mechanism to try before escalating to phototherapy or a systemic option.

For unstable vitiligo that's actively and rapidly spreading, stabilizing the disease itself typically takes priority over repigmentation, since new depigmentation can outpace whatever a topical is repigmenting elsewhere; a dermatologist manages that sequencing rather than starting a repigmentation-focused treatment on skin that's still actively losing pigment.

Who Is — and Isn't — a Good Candidate

Ruxolitinib cream's approval covers nonsegmental vitiligo specifically, in people aged 12 and older; segmental vitiligo — the rarer form that typically appears on one side of the body in a band-like pattern and behaves differently biologically — was not the population studied in the pivotal trials 1. People with widespread vitiligo covering a large fraction of the body surface may find a topical cream impractical to apply everywhere consistently, which is part of why phototherapy or a systemic option sometimes makes more sense for extensive disease.

As with any newer targeted medication, ongoing follow-up with a prescriber is part of appropriate use, both to track whether treatment is working on the timeline the trials suggest and to reassess the plan if it isn't.

Setting Realistic Expectations

Ruxolitinib cream is a genuine advance — it's the first topical treatment with an FDA approval specifically for repigmenting vitiligo rather than an off-label borrow from another condition — but it isn't a cure, and the trial data show a meaningful minority, not a majority, reaching substantial facial repigmentation even after a year of continued use 1. Complete, even repigmentation across all affected areas is not the typical outcome; partial improvement, particularly on the face, is the more realistic expectation to carry in.

Whether ruxolitinib is worth starting, how long to try it before judging it, and whether to combine it with phototherapy are all decisions that depend on which body areas are affected, how long vitiligo has been active, and personal priorities about how much change matters — conversations best had directly with a dermatologist experienced in treating vitiligo.

Common questions

The trials that led to its approval measured results at 24 weeks and continued to see improvement through a full year of use, so meaningful visible change typically takes months, not weeks. A patch that looks the same after four to six weeks isn't necessarily a sign the treatment isn't working.

No. The face tends to repigment more than other areas, while hands and feet are typically the slowest and least complete to respond, a pattern seen consistently in the pivotal trials. This is thought to relate to how many hair-follicle pigment reservoirs a given area has.

No. It's an effective treatment that produces significantly more repigmentation than an inactive cream, but only a minority of users reach substantial facial repigmentation even after a year, and complete, even repigmentation across all affected skin isn't the typical outcome.

Yes, combining phototherapy and cream is common in practice, since the two work through different mechanisms — light stimulates melanocyte activity directly, while ruxolitinib interrupts the immune attack on those cells. Many dermatologists use them together rather than choosing one over the other.

It's approved for nonsegmental vitiligo, the more common form that tends to appear on both sides of the body, in people 12 and older. Segmental vitiligo, which typically appears in a band on one side of the body, wasn't the population studied in the trials that led to approval.

Some UV exposure to treated areas is generally encouraged as part of treatment, since light helps stimulate the melanocyte activity that drives repigmentation, which is also why phototherapy and ruxolitinib are often paired. A dermatologist can advise on balancing sun exposure with everyday sun protection for unaffected skin.

Related

Say it back

How would you explain this to someone you love?

Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

When to Involve a Dermatologist Before Starting

  • —rapidly spreading new patches of depigmentation over weeks
  • —vitiligo patches that become inflamed, painful, or start to blister
  • —signs of infection at a treated area — increasing redness, warmth, or discharge
  • —new or worsening eye or vision changes, which can occasionally accompany autoimmune pigment conditions

This article explains how ruxolitinib cream works for vitiligo in general terms; it isn't a treatment recommendation. A dermatologist can determine whether it's appropriate for a specific case and how to combine it with other treatment.

References

  1. 1.Rosmarin D, Passeron T, Pandya AG, et al. (2022). Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo. New England Journal of Medicine. doi:10.1056/NEJMoa2118828 ✓Supports that topical ruxolitinib produced significantly greater facial and total-body repigmentation than vehicle in the TRuE-V1/V2 trials, with continued improvement through one year, in nonsegmental vitiligo ages 12 and older.
  2. 2.National Institute of Arthritis and Musculoskeletal and Skin Diseases (2024). Vitiligo. NIH / NIAMS. link ✓Supports the definition of vitiligo as an autoimmune condition destroying melanocytes, with no cure but treatments that can stabilize and repigment.
  3. 3.Bae JM, Jung HM, Hong BY, et al. (2017). Phototherapy for Vitiligo: A Systematic Review and Meta-analysis. JAMA Dermatology. link ✓Supports that narrowband UVB phototherapy produces meaningful vitiligo repigmentation on its own, with response building over months of treatment.

3 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — every citation independently verified. Editorial policy

← Back to the health library